Skip to main content
Publications
Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwama N, Waldron-Lynch M, Davis KL, Giovannini M, Awad MM. Improved survival outcomes in patients with MET-dysregulated advanced NSCLC treated with MET inhibitors: results of a multinational retrospective chart review. Clin Lung Cancer. 2023 Nov;24(7):641-650.e. doi: 10.1016/j.cllc.2023.08.011
Weber JS, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, Van Akkool A, Menzies A, Long G, Taylor AM, Haanen J, Zijlker L, Davis KL, Karanth S, Shah RM, Connolly L, Norton D. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600–mutated stage III/IV melanoma. Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.
Goyal RK, Frugier G, Rombi J, Esterberg L, Davis KL, Hlavacek P, Ren J, Schepart A, Aydin D, DeBonaventura M. Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: a real-world observational chart review study. Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL.
Fasching PA, Hall PS, Chang L, Parikh R, Hitchens A, Davis KL, Sjekloca N, Summerhayes M, Ntalla I, Derrien Ansquer V, Bergamaco E, Ghabaireh M. Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER). Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 11, 2023. Berlin, Germany.
Oikonomidou O, Galve-Calvo E, Wockel A, Parikh R, Hitchens A, Chen C, Gauthier E, Li B, Derrien Ansquer V, Frugier G, Jimenez M, Davis KL, Broughton EI. Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2_ advanced breast cancer in Europe. Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 2023. Berlin, Germany.
Lin S, Kahangire DA, Nagar S, Ahn M, Affi R, Agulnik J, Shih J, Hockmair MJ, Tufman A, Debieuvre D, Chow J, Jimenez M, Davis KL, Sandelin M, Veluswamy R. Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study. Poster presented at the European Lung Cancer Congress 2023; March 31, 2023. Copenhagen, Demark.
Simmons DJ, Blank SV, Nagar S, Nham T, Long GH, Davis KL, Wetherill G, Munley J, McLaurin K. Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: retrospective US cohort study. Poster presented at the SGO 2023 Annual Meeting on Women's Cancer; March 27, 2023. Tampa, FL.
Ahn M, Kang JH, Kim S, Kahangarie D, Nagar SP, Davis KL, Jimenez M, Seo M, Jung M, Sandelin M, Cho BC. Treatment (tx) patterns and outcomes in resectable early-stage NSCLC in South Korea: subgroup analysis of a global real-world (rw) study. Poster presented at the ESMO Asian Congress 2023; December 2, 2023. Singapore, China. [abstract] Ann Oncol. 2023; 34(Suppl 4):S1646-53.
Furqan M, Karanth S, Goyal RK, Shih Y, Cai B, Rombi J, Davis KL, Caro N, Saliba TR. Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14). Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023; 4((Suppl 16):e21112.